106	AGN-241751
AGN-241751 &&&&& Introduction &&&&& &&&&& &&&&& '''AGN-241751''' is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD). It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018. Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD. Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel. As of May 2018, the drug is in phase I clinical trials. &&&&& &&&&& See also &&&&& * List of investigational antidepressants &&&&& &&&&& References &&&&& &&&&& &&&&& External links &&&&& * AGN-241751 - AdisInsight &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& 